Printer Friendly

CAMBRIDGE BIOTECH CORPORATION AND GENENTECH, INC. AGREE TO VACCINE ALLIANCE

 CAMBRIDGE BIOTECH CORPORATION AND GENENTECH,
 INC. AGREE TO VACCINE ALLIANCE
 WORCESTER, Mass., Sept. 14 /PRNewswire/ -- Cambridge Biotech Corporation (NASDAQ: CBCX) today announced it has agreed to license its proprietary QS-21 Stimulon(tm) adjuvant to Genentech, Inc.(NYSE: GNE) for use in an AIDS vaccine. The companies expect to sign the definitive agreement next week. CBC's adjuvant is a potent immune system stimulant that has been demonstrated to enhance protective immune responses to vaccinations.
 CBC's agreement with Genentech involves the development of a recombinant vaccine against HIV-1, the virus that causes AIDS, utilizing Genentech's recombinant HIV-1 protein and the CBC's QS-21 adjuvant. An initial license fee from Genentech to CBC will be paid for the rights to use the QS-21 adjuvant, plus milestone payments as the vaccine using the adjuvant moves through clinical trials. AIDS vaccines are thought to be useful both as a preventive measure and as a treatment for infected patients.
 Genentech will be responsible for completing product development, conducting clinical trials, and marketing the vaccine using the adjuvant. Genentech will purchase the adjuvant and will pay CBC manufacturing fees and a royalty on sales.
 Dr. Patrick J. Leonard, president and CEO of CBC commented, "Genentech has an excellent opportunity to be a leader in the development of a commercial recombinant AIDS vaccine, and we believe that our adjuvant will make an important contribution to its efficacy."
 Genentech already has a sublicense from CBC for the HIV-1 protein gp120, which covers the recombinant protein that will be used by Genentech in the vaccine formulation under evaluation. Adjuvant Background
 CBC has conducted extensive research on a family of purified saponin compounds derived from the soapbark tree Quillaja saponaria, found in South America and Hindustan and cultivated in large commercial scale, producing crude saponin products for applications as varied as heavy industrial cleaners, food emulsifiers and cosmetic additives. CBC's family of purified saponin compounds has been issued a patent under the trade name Stimulon(tm) adjuvant. The compound QS-21 comprises CBC's current adjuvant.
 Among the reported effects of the Stimulon adjuvant are potent stimulation of antibody responses to proteins, including recombinant DNA proteins, and induction of immunological memory. Unlike most other adjuvants, the Stimulon adjuvant not only elicits a humoral response, but also a cell-mediated immunity. In effect, the Stimulon adjuvant elicits the production of targeted cytotoxic (killer) T-cells, or CTLs, even when used with soluble recombinant DNA subunit vaccines. Stimulon also continues to be evaluated as an adjunct to immunotherapy against malignant melanoma by the Memorial Sloan-Kettering Cancer Center.
 Cambridge Biotech Corporation is a leading diagnostic and therapeutic company involved in infectious diseases. The company is developing vaccines, adjuvants and diagnostics for humans and animals.
 -0- 9/14/92
 /CONTACT: Peter P. Hartman, vice president-finance and chief financial officer of Cambridge Biotech, 508-797-5777/
 (CBCX GNE) CO: Cambridge Biotech Corporation; Genetech, Inc. ST: Massachusetts IN: MTC SU: CON


CH -- NE006 -- 8898 09/14/92 08:32 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 14, 1992
Words:486
Previous Article:CAMBRIDGE BIOTECH CORPORATION AND SMITHKLINE BEECHAM SIGN VACCINE ALLIANCE
Next Article:MOTOROLA'S 68040 MICROPROCESSOR POWERS NEW COMMODORE AMIGA 4000
Topics:


Related Articles
CAMBRIDGE BIOTECH GRANTS SUBLICENSE TO GENENTECH FOR DEVELOPMENT OF AIDS VACCINE
CAMBRIDGE BIOTECH CORPORATION AND PASTEUR MERIEUX IN INFLUENZA VACCINE PARTNERSHIP
CAMBRIDGE BIOTECH CORPORATION AND SMITHKLINE BEECHAM SIGN VACCINE ALLIANCE
RESULTS OF HUMAN PHASE I TRIAL OF CAMBRIDGE BIOTECH CORPORATION'S STIMULON ADJUVANT REPORTED
CAMBRIDGE BIOTECH WILL REPORT LOSS FOR FOURTH QUARTER
CAMBRIDGE BIOTECH REPORTS 1992 RESULTS
CAMBRIDGE BIOTECH LICENSES ITS STIMULON (TM) ADJUVANT TO UNIVAX BIOLOGICS FOR PRODUCTION OF POLYCLONAL ANTIBODY PRODUCTS
CAMBRIDGE BIOTECH LICENSES ITS STIMULON ADJUVANT TO AMERICAN CYANAMID
CAMBRIDGE BIOTECH CORPORATION'S STIMULON ADJUVANT IN PHASE I TRIAL WITH GENENTECH HIV-1 VACCINE
HEARING SET FOR JULY 15, 1996 ON CONFIRMATION OF CAMBRIDGE BIOTECH'S PLAN OF REORGANIZATION

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters